Journal article
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer
Sheau W Lok, James R Whittle, Francois Vaillant, Charis E Teh, Louisa L Lo, Antonia N Policheni, Alice RT Bergin, Jayesh Desai, Sarah Ftouni, Luke C Gandolfo, Danny Liew, He K Liu, G Bruce Mann, Kate Moodie, Anand Murugasu, Bhupinder Pal, Andrew W Roberts, Mark A Rosenthal, Kylie Shackleton, Maria Joao Silva Show all
Cancer Discovery | AMER ASSOC CANCER RESEARCH | Published : 2019
Grants
Awarded by National Health and Medical Research Council, Australia (NHMRC)
Awarded by Victorian State Government through Victorian Cancer Agency
Awarded by National Breast Cancer Foundation (NBCF)
Awarded by NHMRC Peter Doherty Early Career Fellowship
Awarded by NHMRC Career Development Fellowship
Awarded by Victorian Cancer Agency Early Career Seed Grant
Awarded by NHMRC Project Grant
Awarded by NHMRC Research Fellowships
Funding Acknowledgements
The authors would like to thank the patients who participated in this study, as well as their referring doctors. We are grateful to P. Sherman and J. Hicks for expert assistance in helping to conduct the study; M. Bisignano in the Department of Anatomical Pathology, Royal Melbourne Hospital, for assistance; staff at the Royal Melbourne Hospital Tissue Bank for support; V. Bryant, J. Tempany, L. Beaton, and I. Wicks for assistance with the immune phenotyping; L. Whitehead for assistance with imaging and computation, and L. Garrett for providing independent data monitoring oversight for the study. We thank J. Leverson, M. Mabry, L. Unicombe, V. Komlosi, M. Mobasher, S. Rafii, D. Sampath, M.A. Anderson, and O. Kondrashova for helpful discussions. Coded breast tumor samples were provided by the Victorian Cancer Biobank (which is supported by the Victorian Government). This work was supported by AbbVie and Roche/Genentech, the National Health and Medical Research Council, Australia (NHMRC; 1016701, 1040978, 1054618, 1078763, and 1113133); NHMRC IRIISS; the Victorian State Government through Victorian Cancer Agency funding (TRP13041) and Operational Infrastructure Support; the Australian Cancer Research Foundation; The National Breast Cancer Foundation (NBCF; NT-13-06); The Qualtrough Cancer Research Fund; and The Joan Marshall Breast Cancer Research Fund. J.R. Whittle was supported by an NHMRC/NBCF Research Fellowship and the Royal Australasian College of Physicians; C.E. Teh by an NHMRC Peter Doherty Early Career Fellowship (1089072); A.N. Policheni by a Cancer Council Victoria Postdoctoral Research Fellowship; S.-J. Dawson by a CSL Centenary Fellowship; D.H.D. Gray by an NHMRC Career Development Fellowship (1090236); B. Pal by a Victorian Cancer Agency Early Career Seed Grant (13-035) and NHMRC Project Grant (1100807). NHMRC Research Fellowships have been awarded to G.K. Smyth (1058892), J.E. Visvader (1037230), and G.J. Lindeman (1078730).